CRL-2408 NK-92MI 人恶性非霍奇金**瘤患者的自然杀伤细胞

如果您对该产品感兴趣的话，可以
产品名称： NK-92MI
产品型号：CRL-2408人恶性非霍奇金**瘤患者的自然杀伤细胞
产品展商：美国标准生物品收藏中心（ATCC）
产品文档：无相关文档

简单介绍

CRL-2408 NK-92MI 人恶性非霍奇金**瘤患者的自然杀伤细胞，原代细胞|细胞系|细胞株|菌种；细胞库管理规范，提供的细胞株背景清楚，提供参考文献和培养条件！

产品描述

CRL-2408 NK-92MI 人恶性非霍奇金**瘤患者的自然杀伤细胞

ATCC^® Number:

CRL-2408™

Price:

Designations:	NK-92MI
Depositors:	ZelleRx Corporation
Biosafety Level:	1
Shipped:	frozen
Medium & Serum:	See Propagation
Growth Properties:	suspension, multicell aggregates
Organism:	Homo sapiens (human)
Morphology:	lymphoblast
Source:	Disease: malignant non-Hodgkin's lymphoma Cell Type: natural killer cell; NK cell;
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Age:	50 years
Gender:	male
Ethnicity:	Caucasian, White
Comments:	NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. NK-92MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived from the NK-92 (ATCC CRL-2407) cell line by transfection. The parental cells were transfected with human IL-2 cDNA in the retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection is stable, most likely due to integration of the vector into genomic DNA. The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. NK-92 and derivative cell line NK-92MI have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. The parental IL-2 dependent cell line is available as CRL-2407 (NK-92). NK-92MI was shown to contain, express, and synthesize the hIL-2. A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
Propagation:	ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%. Temperature: 37.0°C Vessels with plug-seal caps must be used to prevent evaporation of the culture medium. When using vessels with plug-seal caps, gas the headspace of the vessels with 5% ± 1% CO2. Either a standard incubator or a 5.0% ± 1.0% CO2 incubator may then be used.
Subculturing:	Protocol: CRL-2408 cell aggregates must be dispersed every 2 to 3 days by pipetting up and down on the back of the flask to produce a single cell suspension. Cell counts should be performed every 2 to 3 days to determine the viable cell density.Centrifugation and replacement of culture medium may be performed if needed to achieve the appropriate cell density.Maintain cell density between 2 X 10 (5) and 1 X 10 (6) viable cells/ml.
Preservation:	Freeze medium: FBS, 90%; DMSO, 10% Storage temperature: liquid nitrogen vapor phase
Related Products:	recommended serum:ATCC 30-2020 recommended serum:ATCC 30-2040 parental cell line:ATCC CRL-2407
References:	38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260 38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666 40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!

温馨提示：为规避购买风险，建议您在购买前务必确认供应商资质与产品质量。
免责申明：以上内容为注册会员自行发布，若信息的真实性、合法性存在争议，平台将会监督协助处理，欢迎举报

产品目录

产品资料

NK-92MI